Triptolide alleviates the development of inflammation in ankylosing spondylitis via the NONHSAT227927.1/JAK2/STAT3 pathway

Ding,Xiang; Liu,Jian; Sun,Yanqiu; Chen,Xiaolu

doi:10.3892/etm.2023.12305

Triptolide alleviates the development of inflammation in ankylosing spondylitis via the NONHSAT227927.1/JAK2/STAT3 pathway

Authors:
- Xiang Ding
- Jian Liu
- Yanqiu Sun
- Xiaolu Chen
View Affiliations

Affiliations: First Clinical Medical College, Anhui University of Traditional Chinese Medicine, Hefei, Anhui 230031, P.R. China, Department of Rheumatology and Immunology, First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Hefei, Anhui 230038, P.R. China
Published online on: November 16, 2023 https://doi.org/10.3892/etm.2023.12305
Article Number: 17
Copyright: © Ding et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ankylosing spondylitis (AS) is a chronic inflammatory disease that can destroy the affected joints. Triptolide (TPL), a key active ingredient of the traditional Chinese medicine Tripterygium wilfordii exhibits promising efficacy in rheumatic immune disease with its anti‑inflammatory effects. The present study aimed to elucidate the mechanism of TPL in treatment of AS by regulating the long non‑coding RNA (lncRNA) NONHSAT227927.1. The role and underlying mechanisms of TPL in the development of inflammation in AS were assessed. In vivo, the expression of NONHSAT227927.1 in AS was detected by reverse transcription‑quantitative (RT‑q)PCR. Correlation analysis and binary logistic regression were performed between immune and inflammatory indicators, perception scale scores of patients and NONHSAT227927.1. In vitro, Cell Counting Kit‑8 was used to evaluate the activity of AS‑fibroblast‑like synoviocytes (FLSs) following TPL exposure. AS‑FLS inflammation was assessed by qPCR and ELISA. The interaction between TPL and JAK2 and STAT3 was verified by molecular docking and the JAK2/STAT3 pathway components were detected by western blotting. NONHSAT227927.1 was knocked down by small interfering RNA to determine its role. NONHSAT227927.1 was highly expressed in vivo and positively correlated with disease duration, disease duration, Body mass index (BMI), C‑reactive protein (CRP), Visual analog scale (VAS), Visual analog scale (VAS), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Bath Ankylosing Spondylitis Metrology Index, among which ESR and VAS and BASDAI score were risk factors for NONHSAT227927.1. TPL downregulated pro‑inflammatory factors in AS‑FLSs and inhibited the JAK2/STAT3 pathway via NONHSAT227927.1. TPL inhibited inflammatory factors in AS‑FLSs and alleviated inflammatory responses via the NONHSAT227927.1/JAK2/STAT3 axis.

View Figures

View References

1	Braun J and Sieper J: Ankylosing spondylitis. Lancet. 369:1379–1390. 2007.PubMed/NCBI View Article : Google Scholar
2	Wang R and Ward MM: Epidemiology of axial spondyloarthritis: An update. Curr Opin Rheumatol. 30:137–143. 2018.PubMed/NCBI View Article : Google Scholar
3	van Tubergen A: The changing clinical picture and epidemiology of spondyloarthritis. Nat Rev Rheumatol. 11:110–118. 2015.PubMed/NCBI View Article : Google Scholar
4	Salehi E, Eftekhari R, Oraei M, Gharib A and Bidad K: MicroRNAs in rheumatoid arthritis. Clin Rheumatol. 34:615–628. 2015.PubMed/NCBI View Article : Google Scholar
5	MacFarlane LA, Arant KR, Kostic AM, Mass H, Jones MH, Collins JE, Losina E and Katz JN: Identifying inflammation in knee osteoarthritis: Relationship of synovial fluid white blood cell count to effusion-synovitis on magnetic resonance imaging. Arthritis Care Res (Hoboken). 75:1783–1787. 2023.PubMed/NCBI View Article : Google Scholar
6	Liu L, Chen H, Jiang T and He D: MicroRNA-106b overexpression suppresses synovial inflammation and alleviates synovial damage in patients with rheumatoid arthritis. Mod Rheumatol. 32:1054–1063. 2022.PubMed/NCBI View Article : Google Scholar
7	Garrido-Mesa J and Brown MA: T cell repertoire profiling and the mechanism by which HLA-B27 causes ankylosing spondylitis. Curr Rheumatol Rep. 24:398–410. 2022.PubMed/NCBI View Article : Google Scholar
8	Shah NG, Keraliya A, Nunez DB, Schoenfeld A, Harris MB, Bono CM and Khurana B: Injuries to the rigid spine: What the spine surgeon wants to know. Radiographics. 39:449–466. 2019.PubMed/NCBI View Article : Google Scholar
9	Gouveia EB, Elmann D and Morales MS: Ankylosing spondylitis and uveitis: Overview. Rev Bras Reumatol. 52:742–756. 2012.PubMed/NCBI
10	Yu L, Qu H, Yu Y, Li W, Zhao Y and Qiu G: LncRNA-PCAT1 targeting miR-145-5p promotes TLR4-associated osteogenic differentiation of adipose-derived stem cells. J Cel Mol Med. 22:6134–6147. 2018.PubMed/NCBI View Article : Google Scholar
11	Wang JX, Jing FY, XU YC, Zong HX, Chu YR, Wang C, Chen KM, Tong WQ, Wang XL and Xu SQ: The potential regulatory mechanism of lncRNA 122K13.12 and lncRNA 326C3.7 in ankylosing spondylitis. Front Mol Biosci. 8(745441)2021.PubMed/NCBI View Article : Google Scholar
12	Wapinski O and Chang HY: Long noncoding RNAs and human disease. Trends Cell Biol. 21:354–361. 2011.PubMed/NCBI View Article : Google Scholar
13	Lalevée S and Feil R: Long noncoding RNAs in human disease: Emerging mechanisms and therapeutic strategies. Epigenomics. 7:877–879. 2015.PubMed/NCBI View Article : Google Scholar
14	Han D, Ouyang G, Pan P and Yuan Y: Upregulated lncRNA-NEF predicts recurrence and poor treatment outcomes of ankylosing spondylitis. Immun Inflamm Dis. 10(e627)2022.PubMed/NCBI View Article : Google Scholar
15	Li Y, Zhang S, Zhang C and Wang M: LncRNA MEG3 inhibits the inflammatory response of ankylosing spondylitis by targeting miR-146a. Mol Cell Biochem. 466:17–24. 2020.PubMed/NCBI View Article : Google Scholar
16	Liu W, Huang L, Zhang C and Liu Z: lncRNA MEG3 is downregulated in ankylosing spondylitis and associated with disease activity, hospitalization time and disease duration. Exp Ther Med. 17:291–297. 2019.PubMed/NCBI View Article : Google Scholar
17	Agashe RP, Lippman SM and Kurzrock R: JAK: Not just another kinase. Mol Cancer Ther. 21:1757–1764. 2022.PubMed/NCBI View Article : Google Scholar
18	Rosillo MA, Sánchez-Hidalgo M, Sánchez-Fidalgo S, Aparicio-Soto M, Villegas I and Alarcón-de-la-Lastra C: Dietary extra-virgin olive oil prevents inflammatory response and cartilage matrix degradation in murine collagen-induced arthritis. Eur J Nut. 55:315–325. 2016.PubMed/NCBI View Article : Google Scholar
19	Li WQ, Dehnade F and Zafarullah M: Oncostatin M-induced matrix metalloproteinase and tissue inhibitor of metalloproteinase-3 genes expression in chondrocytes requires Janus kinase/STAT signaling pathway. J Immunol. 166:3491–3498. 2001.PubMed/NCBI View Article : Google Scholar
20	Raychaudhuri SK and Raychaudhuri SP: Janus kinase/signal transducer and activator of transcription pathways in spondyloarthritis. Curr Opin Rheumatol. 29:311–316. 2017.PubMed/NCBI View Article : Google Scholar
21	Ding X, Liu J and Sun Y: Expression of long non-coding RNA NONHSAT227927.1 and its effect on the JAK2/STAT3 signaling pathway and inflammation in patients with ankylosing spondylitis. Exp Ther Med. 25(231)2023.PubMed/NCBI View Article : Google Scholar
22	Li XJ, Jiang ZZ and Zhang LY: Triptolide: Progress on research in pharmacodynamics and toxicology. J Ethnopharmacol. 155:67–79. 2014.PubMed/NCBI View Article : Google Scholar
23	Yan P and Sun X: Triptolide: A new star for treating human malignancies. J Cancer Res Ther. 14 (Suppl):S271–S275. 2018.PubMed/NCBI View Article : Google Scholar
24	American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 36 (Suppl 1):S67–S74. 2013.PubMed/NCBI View Article : Google Scholar
25	Ji W, Lu Y, Ma Z, Gan K, Liu Y, Cheng Y, Xu J, Liu S, Guo Y, Han S, et al: Triptolide attenuates inhibition of ankylosing spondylitis-derived mesenchymal stem cells on the osteoclastogenesis through modulating exosomal transfer of circ-0110634. J Orthop Translat. 36:132–144. 2022.PubMed/NCBI View Article : Google Scholar
26	Wang G, Cai J, Zhang J and Li C: Mechanism of triptolide in treating ankylosing spondylitis through the anti-ossification effect of the BMP/Smad signaling pathway. Mol Med Rep. 17:2731–2737. 2018.PubMed/NCBI View Article : Google Scholar
27	van der Linden S, Valkenburg HA and Cats A: Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 27:361–368. 1984.PubMed/NCBI View Article : Google Scholar
28	Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, Landewé RBM, Van den Bosch FE, Boteva B, Bremander A, et al: ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 Update. Ann Rheum Dis. 82:19–34. 2023.PubMed/NCBI View Article : Google Scholar
29	Landewé R, Dougados M, Mielants H, van der Tempel H and van der Heijde D: Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine. Ann Rheum Dis. 68:863–867. 2009.PubMed/NCBI View Article : Google Scholar
30	Poddubnyy D, Protopopov M, Haibel H, Braun J, Rudwaleit M and Sieper J: High disease activity according to the ankylosing spondylitis disease activity score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: Results from the GErman SPondyloarthritis inception cohort. Ann Rheum Dis. 75:2114–2118. 2016.PubMed/NCBI View Article : Google Scholar
31	Qin X, Zhu B, Jiang T, Tan J, Wu Z, Yuan Z, Zheng L and Zhao J: miR-17-5p regulates heterotopic ossification by targeting ANKH in ankylosing spondylitis. Mol Ther Nucleic Acids. 18:696–707. 2019.PubMed/NCBI View Article : Google Scholar
32	Zhong H and Zhong M: LINC00311 is overexpressed in ankylosing spondylitis and predict treatment outcomes and recurrence. BMC Musculoskelet Disord. 20(278)2019.PubMed/NCBI View Article : Google Scholar
33	van der Heijde D, Ramiro S, Landewé R, Baraliakos X, Van den Bosch F, Sepriano A, Regel A, Ciurea A, Dagfinrud H, Dougados M, et al: 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 76:978–991. 2017.PubMed/NCBI View Article : Google Scholar
34	Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, Haroon N, Borenstein D, Wang R, Biehl A, et al: 2019 update of the American college of rheumatology/spondylitis association of America/spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 71:1599–1613. 2019.PubMed/NCBI View Article : Google Scholar
35	Li N, Chen Z, Feng W, Gong Z, Lin C, Chen J, Chu C and Xu Q: Triptolide improves chondrocyte proliferation and secretion via down-regulation of miR-221 in synovial cell exosomes. Phytomedicine. 107(154479)2022.PubMed/NCBI View Article : Google Scholar
36	Ji W, Liu S, Zhao X, Guo Y, Xia S, Lu Y, Yin M and Xu X: Triptolide inhibits proliferation, differentiation and induces apoptosis of osteoblastic MC3T3-E1 cells. Mol Med Rep. 16:7391–7397. 2017.PubMed/NCBI View Article : Google Scholar
37	Luo X, Gu Y, Tao X, Serhan CN and Ji RR: Resolvin D5 inhibits neuropathic and inflammatory pain in male but not female mice: distinct actions of D-series resolvins in chemotherapy-induced peripheral neuropathy. Front Pharmacol. 10(745)2019.PubMed/NCBI View Article : Google Scholar
38	Hur K, Kim SH and Kim JM: Potential implications of long noncoding RNAs in autoimmune diseases. Immune Netw. 19(e4)2019.PubMed/NCBI View Article : Google Scholar
39	Hamdy SM, Ali MS, Abd El-Hmid RG, Abdelghaffar NK and Abdelaleem OO: Role of long non coding RNAs, NEAT1 and Lnc-DC expression in pediatric immune thrombocytopenic purpura. Rep Biochem Mol Biol. 11:635–643. 2023.PubMed/NCBI View Article : Google Scholar
40	Cai B, Cai J, Yin Z, Jiang X, Yao C, Ma J, Xue Z, Miao P, Xiao Q, Cheng Y, et al: Long non-coding RNA expression profiles in neutrophils revealed potential biomarker for prediction of renal involvement in SLE patients. Rheumatology (Oxford). 60:1734–1746. 2021.PubMed/NCBI View Article : Google Scholar
41	Morchikh M, Cribier A, Raffel R, Amraoui S, Cau J, Severac D, Dubois E, Schwartz O, Bennasser Y and Benkirane M: HEXIM1 and NEAT1 long non-coding RNA form a multi-subunit complex that regulates DNA-mediated innate immune response. Mol Cell. 67:387–399.e5. 2017.PubMed/NCBI View Article : Google Scholar
42	Li X, Chai W, Zhang G, Ni M, Chen J, Dong J, Zhou Y, Hao L, Bai Y and Wang Y: Down-regulation of lncRNA-AK001085 and its influences on the diagnosis of ankylosing spondylitis. Med Sci Monit. 23:11–16. 2017.PubMed/NCBI View Article : Google Scholar
43	Ding M, Guan TJ, Wei CY and Chen BH: Identification of pathways significantly associated with spondyloarthropathy/ankylosing spondylitis using the sub-pathway method. Mol Med Rep. 18:3825–3833. 2018.PubMed/NCBI View Article : Google Scholar
44	Marcus DM: Comparison of Tripterygium wilfordii Hook F with methotrexate in the treatment of rheumatoid arthritis. Ann Rheum Dis. 73(e56)2014.PubMed/NCBI View Article : Google Scholar
45	Tao X, Younger J, Fan FZ, Wang B and Lipsky PE: Benefit of an extract of Tripterygium wilfordii Hook F in patients with rheumatoid arthritis: A double-blind, placebo-controlled study. Arthritis Rheum. 46:1735–1743. 2002.PubMed/NCBI View Article : Google Scholar
46	Matta R, Wang X, Ge H, Ray W, Nelin LD and Liu Y: Triptolide induces anti-inflammatory cellular responses. Am J Transl Res. 1:267–282. 2009.PubMed/NCBI
47	Chen BJ: Triptolide, a novel immunosuppressive and anti-inflammatory agent purified from a Chinese herb Tripterygium wilfordii Hook F. Leuk Lymphoma. 42:253–265. 2001.PubMed/NCBI View Article : Google Scholar
48	Su MX, Zhou WD, Lan J, Di B and Hang TJ: Rapid and sensitive analysis of multiple bioactive constituents in tripterygium glycosides tablets using liquid chromatography coupled with time-of-flight mass spectrometry. J Sep Sci. 38:804–812. 2015.PubMed/NCBI View Article : Google Scholar
49	Wang QL, Sun M, Wang DT, et al: Observation on the efficacy of Tripterygium wilfordii polyglycosides combined with methotrexate in the treatment of ankylosing spondylitis. World Chin Med. 17:2486–2489. 2002.(In Chinese).
50	Ji W, Chen Y, Zhao X, Guo Y, Zhong L, Li H, Wang D and Song Y: Beneficial effects of tripterygium glycosides tablet on biomarkers in patients with ankylosing spondylitis. Mol Med Rep. 12:684–690. 2015.PubMed/NCBI View Article : Google Scholar
51	Ye X, Li W, Yan Y, Mao C, Cai R, Xu H and Yang X: Effects of cytochrome P4503A inducer dexamethasone on the metabolism and toxicity of triptolide in rat. Toxicol Lett. 192:212–220. 2010.PubMed/NCBI View Article : Google Scholar
52	Lee HI, Kim HJ, Jo S, Shim SC, Kim TH, Won EJ and Kim TJ: IL-6 activates pathologic Th17 cell via STAT 3 phosphorylation in inflammatory joint of ankylosing spondylitis. Biochem Biophys Res Commun. 620:69–75. 2022.PubMed/NCBI View Article : Google Scholar
53	Zhong Z, Wen Z and Darnell JE Jr: Stat3: A STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science. 264:95–98. 1994.PubMed/NCBI View Article : Google Scholar
54	Fang YY, Wan L, Dong WZ, Wen JT and Liu J: Effect of triptolide in improving platelet activation in patients with ankylosing spondylitis by regulating VEGFA,SDF-1,CXCR4 pathway. Zhongguo Zhong Yao Za Zhi. 44:3520–3525. 2019.PubMed/NCBI View Article : Google Scholar : (In Chinese).